Funding Daily Summary
Funding Daily Summary: What Happened on November 15, 2026
Oyster raises $60 million for tau-degrader research
The London startup will use the Series A-2 financing to advance a preclinical Alzheimer’s candidate and other programs.
Today in brief
Oyster Therapeutics secured $60 million in Series A-2 funding for its preclinical candidate, designed to degrade disease-linked tau.1
Also worth knowing
-
4BIO Capital led the round, joined by Eli Lilly and other new and existing investors. CEO Rob Johnson said Oyster aims to take its tau degrader into clinical testing.1